董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Saeed Motahari | 男 | President, Chief Executive Officer and Director | 51 | 未披露 | 未持股 | 2017-04-18 |
| John N. Kapoor | 男 | Director | 73 | 55.07万美元 | 未持股 | 2017-04-18 |
| Pierre Lapalme | 男 | Director | 76 | 29.94万美元 | 未持股 | 2017-04-18 |
| Patrick P. Fourteau | 男 | Director | 69 | 32.14万美元 | 未持股 | 2017-04-18 |
| Steven Meyer | 男 | Chairman of the Board of Directors | 60 | 30.64万美元 | 未持股 | 2017-04-18 |
| Brian Tambi | 男 | Director | 71 | 26.64万美元 | 未持股 | 2017-04-18 |
| Theodore H. Stanley | 男 | Director | 76 | 27.44万美元 | 未持股 | 2017-04-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Franc Del Fosse | 男 | General Counsel and Corporate Secretary | 45 | 66.59万美元 | 未持股 | 2017-04-18 |
| Saeed Motahari | 男 | President, Chief Executive Officer and Director | 51 | 未披露 | 未持股 | 2017-04-18 |
| Santosh Vetticaden | -- | Chief Medical Officer | 57 | 未披露 | 未持股 | 2017-04-18 |
| Darryl S. Baker | 男 | Chief Financial Officer | 48 | 68.09万美元 | 未持股 | 2017-04-18 |
董事简历
中英对照 | 中文 | 英文- Saeed Motahari
-
Saeed Motahari自2017年4月17日起担任我们的总裁兼首席执行官兼董事会成员。在加入公司之前，Motahari先生于2014年5月至2017年4月担任Purdue Pharma L.P.的首席商务官。Motahari从2004年到2014年在雅培公司和AbbVie任职，包括担任美国Specialty Brands-New Launchings Vice President。Motahari先生还负责肾脏、肿瘤学、内分泌学、急性护理、病毒学和神经科学治疗领域的专业特许经营。Motahari先生还领导了雅培公司、百时美施贵宝和Hoffmann-La Roche在管理式医疗、商业运营、全球分析和新产品开发方面的各种商业组织。Motahari先生在加拿大蒙特利尔康科迪亚大学（Concordia University）获得生物学学士学位，并持有商学硕士学位。
Saeed Motahari has served as our President and Chief Executive Officer and member of the Board since April 17 2017. Prior to joining the Company, Mr. Motahari served as the Chief Commercial Officer of Purdue Pharma L.P. from May 2014 to April 2017. From 2004 to 2014 Mr. Motahari worked at Abbott Laboratories and AbbVie, including serving as Vice President of US Specialty Brands - New Launches. Mr. Motahari also held P&L responsibility for Specialty Franchises in the Renal, Oncology, Endocrinology, Acute Care, Virology and Neuroscience therapeutic areas. Mr. Motahari has also led various commercial organizations at Abbott Laboratories, Bristol-Myers Squibb and Hoffmann-La Roche in managed care, commercial operations, global analytics and new product development. Mr. Motahari received a BS in Biology and holds a Master’s of Business degree from Concordia University, Montreal, Canada. - Saeed Motahari自2017年4月17日起担任我们的总裁兼首席执行官兼董事会成员。在加入公司之前，Motahari先生于2014年5月至2017年4月担任Purdue Pharma L.P.的首席商务官。Motahari从2004年到2014年在雅培公司和AbbVie任职，包括担任美国Specialty Brands-New Launchings Vice President。Motahari先生还负责肾脏、肿瘤学、内分泌学、急性护理、病毒学和神经科学治疗领域的专业特许经营。Motahari先生还领导了雅培公司、百时美施贵宝和Hoffmann-La Roche在管理式医疗、商业运营、全球分析和新产品开发方面的各种商业组织。Motahari先生在加拿大蒙特利尔康科迪亚大学（Concordia University）获得生物学学士学位，并持有商学硕士学位。
- Saeed Motahari has served as our President and Chief Executive Officer and member of the Board since April 17 2017. Prior to joining the Company, Mr. Motahari served as the Chief Commercial Officer of Purdue Pharma L.P. from May 2014 to April 2017. From 2004 to 2014 Mr. Motahari worked at Abbott Laboratories and AbbVie, including serving as Vice President of US Specialty Brands - New Launches. Mr. Motahari also held P&L responsibility for Specialty Franchises in the Renal, Oncology, Endocrinology, Acute Care, Virology and Neuroscience therapeutic areas. Mr. Motahari has also led various commercial organizations at Abbott Laboratories, Bristol-Myers Squibb and Hoffmann-La Roche in managed care, commercial operations, global analytics and new product development. Mr. Motahari received a BS in Biology and holds a Master’s of Business degree from Concordia University, Montreal, Canada.
- John N. Kapoor
-
John N. Kapoor博士自1990年10月担任董事会主席。Kapoor博士从2001年3月到2002年5月担任临时首席执行官，并从2002年5月到2002年12月担任首席执行官。Kapoor博士是EJ金融股份有限公司总裁，该公司是一家健康护理咨询公司和投资公司。Kapoor博士还是Insys疗法公司（纳斯达克交易代码：INSY）董事会主席，该公司是一家上市的关注于疼痛治疗与肿瘤的药物发展公司，该公司在2010年10月被NeoPharm股份有限公司（此前是一家上市的生物化学制药公司）收购。在被NeoPharm公司收购前，Kapoor博士是该公司董事会主席。按照我们1989年9月20日与John N. Kapoor 信托公司签订的协议，John N. Kapoor博士是受益人以及单一受托人，同时还是董事会主席。Kapoor信托有权指定一人被提名并被董事会推荐参加董事选举。Kapoor博士正是因为此被Kapoor信托公司指定的。
John N. Kapoor has served as the Chairman of our Board since October 1990. Dr. Kapoor served as our interim Chief Executive Officer from March 2001 to May 2002 and as our Chief Executive Officer from May 2002 to December 2002. Dr. Kapoor is the President of EJ Financial Enterprises, Inc., a healthcare consulting and investment company. Dr. Kapoor is a director and former chairman, President and Chief Executive Officer of Insys Therapeutics, Inc. (NASDAQ: INSY), a publicly held drug development company focused on pain and oncology, into which NeoPharm, Inc. (previously a publicly held biopharmaceutical company) merged in October 2010. Prior to NeoPharm's merger, Dr. Kapoor was the chairman of its board of directors. Previously, Dr. Kapoor was the chairman of the board of directors of Option Care, Inc., a leading provider of home infusion pharmacy and specialty pharmacy services, which was acquired by Walgreen Co. in August 2007. Dr. Kapoor received his Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo and a B.S. in Pharmacy from Bombay University in India. Under agreements between Akorn and the John N. Kapoor Trust dated 9/20/89 (the "Kapoor Trust"), the beneficiary and sole trustee of which is Dr. John N. Kapoor, the Kapoor Trust is entitled to designate one individual to be nominated and recommended by our Board for election as a director. Dr. Kapoor was designated by the Kapoor Trust for this purpose. - John N. Kapoor博士自1990年10月担任董事会主席。Kapoor博士从2001年3月到2002年5月担任临时首席执行官，并从2002年5月到2002年12月担任首席执行官。Kapoor博士是EJ金融股份有限公司总裁，该公司是一家健康护理咨询公司和投资公司。Kapoor博士还是Insys疗法公司（纳斯达克交易代码：INSY）董事会主席，该公司是一家上市的关注于疼痛治疗与肿瘤的药物发展公司，该公司在2010年10月被NeoPharm股份有限公司（此前是一家上市的生物化学制药公司）收购。在被NeoPharm公司收购前，Kapoor博士是该公司董事会主席。按照我们1989年9月20日与John N. Kapoor 信托公司签订的协议，John N. Kapoor博士是受益人以及单一受托人，同时还是董事会主席。Kapoor信托有权指定一人被提名并被董事会推荐参加董事选举。Kapoor博士正是因为此被Kapoor信托公司指定的。
- John N. Kapoor has served as the Chairman of our Board since October 1990. Dr. Kapoor served as our interim Chief Executive Officer from March 2001 to May 2002 and as our Chief Executive Officer from May 2002 to December 2002. Dr. Kapoor is the President of EJ Financial Enterprises, Inc., a healthcare consulting and investment company. Dr. Kapoor is a director and former chairman, President and Chief Executive Officer of Insys Therapeutics, Inc. (NASDAQ: INSY), a publicly held drug development company focused on pain and oncology, into which NeoPharm, Inc. (previously a publicly held biopharmaceutical company) merged in October 2010. Prior to NeoPharm's merger, Dr. Kapoor was the chairman of its board of directors. Previously, Dr. Kapoor was the chairman of the board of directors of Option Care, Inc., a leading provider of home infusion pharmacy and specialty pharmacy services, which was acquired by Walgreen Co. in August 2007. Dr. Kapoor received his Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo and a B.S. in Pharmacy from Bombay University in India. Under agreements between Akorn and the John N. Kapoor Trust dated 9/20/89 (the "Kapoor Trust"), the beneficiary and sole trustee of which is Dr. John N. Kapoor, the Kapoor Trust is entitled to designate one individual to be nominated and recommended by our Board for election as a director. Dr. Kapoor was designated by the Kapoor Trust for this purpose.
- Pierre Lapalme
-
Pierre Lapalme，自2009年12月起担任本公司董事。在整个职业生涯中，他曾在多个全球性生命科学公司担任了众多的高级管理职位。他曾是Ciba-Geigy的销售营销高级副总裁，该公司就是后来的诺华公司；他也曾担任Rhone-Poulenc Pharmaceuticals加拿大和北美地区的首席执行官和董事长；以及Rhone-Poulenc-Rorer 北美地区（现赛诺菲 - 安万特公司）的副总裁和首席执行官，他负责监督北美和中美洲处方产品的开发、制造和销售。他曾担任了全国医药理事会的董事，也曾是加拿大的药品制造商协会的董事，在该协会重新制定药品专利保护条款时，他发挥了重要的作用。不久之前，他是Sciele Pharma的董事和董事长，该公司后来被Shionogi and Co. Ltd收购。他目前担任 Biomarin、Pediapharm、GlyPharma Therapeutics的董事长， 以及Algorithme Pharma和Insy's herapeutics的董事，后者是亚利桑那州凤凰城的特种药品制药公司。他曾就读于西安大略大学和法国的欧洲工商管理学院。
Pierre Lapalme has served on our Board since March 2011. Mr. Lapalme is Chairman of the Board of Pediapharm Inc., a publicly traded pharmaceutical company traded on the Toronto Stock Exchange, and has served on their Board of Directors since January 2014. From January 2004 to June 2016 Mr. Lapalme served on the Board of Directors of BioMarin Pharmaceutical Inc., a publicly traded pharmaceutical company. From August 2004 until January 2015 Mr. Lapalme served as Chairman of the Board of Directors of BioMarin Pharmaceutical Inc. From 2009 to 2016 Mr. Lapalme served on the Board of Directors of Aeterna Zentaris, Inc., a biopharmaceutical company publicly traded on the Toronto Stock Exchange. From 1995 until his retirement in 2003 he served as the President and Chief Executive Officer of North America Ethypharm, Inc., a drug delivery company. Throughout his career, Mr. Lapalme held numerous senior management positions in the pharmaceutical industry, including Chief Executive Officer and Chairman of the Board of Rhône-Poulenc Pharmaceuticals, Inc., in Canada, from 1979 to 1994 and Senior Vice President and General Manager of North America Ethicals, a division of Rhône-Poulenc Rorer, Inc. now known as Sanofi where he oversaw the development of the ethical pharmaceutical business in the United States, Canada, Mexico, and Central America. Mr. Lapalme served on the board of the National Pharmaceutical Council and was a board member of the Pharmaceutical Manufacturers Association of Canada, where he played a leading role in reinstituting certain patent protection for pharmaceuticals. Mr. Lapalme also previously served on the board of directors of two other public companies: Sciele Pharmaceuticals Inc. from 2000 to 2008 and Bioxel Pharma from 2004 to 2009. He also served on the board of two private biotech companies. Mr. Lapalme studied at the University of Western Ontario and INSEAD France. - Pierre Lapalme，自2009年12月起担任本公司董事。在整个职业生涯中，他曾在多个全球性生命科学公司担任了众多的高级管理职位。他曾是Ciba-Geigy的销售营销高级副总裁，该公司就是后来的诺华公司；他也曾担任Rhone-Poulenc Pharmaceuticals加拿大和北美地区的首席执行官和董事长；以及Rhone-Poulenc-Rorer 北美地区（现赛诺菲 - 安万特公司）的副总裁和首席执行官，他负责监督北美和中美洲处方产品的开发、制造和销售。他曾担任了全国医药理事会的董事，也曾是加拿大的药品制造商协会的董事，在该协会重新制定药品专利保护条款时，他发挥了重要的作用。不久之前，他是Sciele Pharma的董事和董事长，该公司后来被Shionogi and Co. Ltd收购。他目前担任 Biomarin、Pediapharm、GlyPharma Therapeutics的董事长， 以及Algorithme Pharma和Insy's herapeutics的董事，后者是亚利桑那州凤凰城的特种药品制药公司。他曾就读于西安大略大学和法国的欧洲工商管理学院。
- Pierre Lapalme has served on our Board since March 2011. Mr. Lapalme is Chairman of the Board of Pediapharm Inc., a publicly traded pharmaceutical company traded on the Toronto Stock Exchange, and has served on their Board of Directors since January 2014. From January 2004 to June 2016 Mr. Lapalme served on the Board of Directors of BioMarin Pharmaceutical Inc., a publicly traded pharmaceutical company. From August 2004 until January 2015 Mr. Lapalme served as Chairman of the Board of Directors of BioMarin Pharmaceutical Inc. From 2009 to 2016 Mr. Lapalme served on the Board of Directors of Aeterna Zentaris, Inc., a biopharmaceutical company publicly traded on the Toronto Stock Exchange. From 1995 until his retirement in 2003 he served as the President and Chief Executive Officer of North America Ethypharm, Inc., a drug delivery company. Throughout his career, Mr. Lapalme held numerous senior management positions in the pharmaceutical industry, including Chief Executive Officer and Chairman of the Board of Rhône-Poulenc Pharmaceuticals, Inc., in Canada, from 1979 to 1994 and Senior Vice President and General Manager of North America Ethicals, a division of Rhône-Poulenc Rorer, Inc. now known as Sanofi where he oversaw the development of the ethical pharmaceutical business in the United States, Canada, Mexico, and Central America. Mr. Lapalme served on the board of the National Pharmaceutical Council and was a board member of the Pharmaceutical Manufacturers Association of Canada, where he played a leading role in reinstituting certain patent protection for pharmaceuticals. Mr. Lapalme also previously served on the board of directors of two other public companies: Sciele Pharmaceuticals Inc. from 2000 to 2008 and Bioxel Pharma from 2004 to 2009. He also served on the board of two private biotech companies. Mr. Lapalme studied at the University of Western Ontario and INSEAD France.
- Patrick P. Fourteau
-
Patrick P. Fourteau，自2011年3月以来一直在本董事会任职。他曾在2008-2010年期间是Shionogi公司的总裁兼首席执行官。在Shionogi收购Sciele Pharma之前，他曾在2003-2008年期间是Sciele Pharma的总裁兼首席执行官（CEO），以及在2004-2008年期间曾在Sciele 的董事会任职。他于2000-2002年期间在inVentiv Health股份有限公司担任全球销售副总裁。他于1995-2000年期间在St. Jude Medical股份有限公司担任若干部门的总裁，以及在1995年之前在Eli Lilly公司担任主管。他是在Harvard大学获得他的工商管理学硕士学位，以及在加州（California）大学Berkeley分校获得他的数学硕士学位的。
Patrick P. Fourteau has served on our Board since March 2011. Since May 2016 Mr. Fourteau has served as the Chairman of the Board of Directors of Repros Therapeutics, Inc. a publicly traded pharmaceutical company. Mr. Fourteau served as the Chief Executive Officer and a member of the Board of Directors of New Haven Pharmaceutical from 2008 to 2017. Mr. Fourteau served as President and Chief Executive Officer of Shionogi from 2008 until 2010. Prior to the acquisition of Sciele Pharma by Shionogi, Mr. Fourteau served as President and CEO of Sciele Pharma from 2003 until 2008 and served on the board of directors of Sciele from 2004 until 2008. Mr. Fourteau served as President of Worldwide Sales of inVentiv Health, Inc. from 2000 to 2002. Mr. Fourteau served as President of various divisions of St. Jude Medical, Inc. from 1995 to 2000 and as an Executive of Eli Lilly and Company prior to 1995. Mr. Fourteau earned his MBA from Harvard University and a B.A. and M.A. in Mathematics from the University of California, Berkeley. - Patrick P. Fourteau，自2011年3月以来一直在本董事会任职。他曾在2008-2010年期间是Shionogi公司的总裁兼首席执行官。在Shionogi收购Sciele Pharma之前，他曾在2003-2008年期间是Sciele Pharma的总裁兼首席执行官（CEO），以及在2004-2008年期间曾在Sciele 的董事会任职。他于2000-2002年期间在inVentiv Health股份有限公司担任全球销售副总裁。他于1995-2000年期间在St. Jude Medical股份有限公司担任若干部门的总裁，以及在1995年之前在Eli Lilly公司担任主管。他是在Harvard大学获得他的工商管理学硕士学位，以及在加州（California）大学Berkeley分校获得他的数学硕士学位的。
- Patrick P. Fourteau has served on our Board since March 2011. Since May 2016 Mr. Fourteau has served as the Chairman of the Board of Directors of Repros Therapeutics, Inc. a publicly traded pharmaceutical company. Mr. Fourteau served as the Chief Executive Officer and a member of the Board of Directors of New Haven Pharmaceutical from 2008 to 2017. Mr. Fourteau served as President and Chief Executive Officer of Shionogi from 2008 until 2010. Prior to the acquisition of Sciele Pharma by Shionogi, Mr. Fourteau served as President and CEO of Sciele Pharma from 2003 until 2008 and served on the board of directors of Sciele from 2004 until 2008. Mr. Fourteau served as President of Worldwide Sales of inVentiv Health, Inc. from 2000 to 2002. Mr. Fourteau served as President of various divisions of St. Jude Medical, Inc. from 1995 to 2000 and as an Executive of Eli Lilly and Company prior to 1995. Mr. Fourteau earned his MBA from Harvard University and a B.A. and M.A. in Mathematics from the University of California, Berkeley.
- Steven Meyer
-
Steven Meyer，自2010年11月以来一直在本董事会任职。在2007年8月-2010年11月期间，他曾是Insys Pharma的一位董事。自2005年11月以来，他一直在一个从事为投资者进行房地产收购、再定位和管理的私有投资公司- JVM Realty公司担任财务总监。在那之前，他曾被一个全球医疗公司- Baxter International股份有限公司所聘用，在那里他在1997年1月-2004年7月期间担任公司会计。他是在Northwestern 大学Kellogg研究生管理学院获得他的金融和会计专业工商管理学硕士学位，以及在Illinois大学Champaign-Urbana分校获得他的经济学学士学位。他是Illinois州的一位注册会计师。
Steven Meyer has served on our Board since November 2010 and has served as our Chairman of the Board since January 9 2017. From August 2007 until November 2010 Mr. Meyer served as a director of Insys Pharma. Mr. Meyer has served as a director of Akorn, Inc., a publicly traded specialty pharmaceutical company, since June 2009. Since November 2005 Mr. Meyer has served as the Chief Financial Officer of JVM Realty Corporation, a private investment firm specializing in the acquisition, re-positioning and management of real estate for investors. Prior to that, Mr. Meyer was employed by Baxter International Incorporated, a global healthcare company, where he served as Corporate Treasurer and International Controller and VP of Global Operations during a 23-year career at this company. Mr. Meyer earned his MBA in finance and accounting from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Economics from the University of Illinois in Champaign-Urbana. He is an Illinois Certified Public Accountant. - Steven Meyer，自2010年11月以来一直在本董事会任职。在2007年8月-2010年11月期间，他曾是Insys Pharma的一位董事。自2005年11月以来，他一直在一个从事为投资者进行房地产收购、再定位和管理的私有投资公司- JVM Realty公司担任财务总监。在那之前，他曾被一个全球医疗公司- Baxter International股份有限公司所聘用，在那里他在1997年1月-2004年7月期间担任公司会计。他是在Northwestern 大学Kellogg研究生管理学院获得他的金融和会计专业工商管理学硕士学位，以及在Illinois大学Champaign-Urbana分校获得他的经济学学士学位。他是Illinois州的一位注册会计师。
- Steven Meyer has served on our Board since November 2010 and has served as our Chairman of the Board since January 9 2017. From August 2007 until November 2010 Mr. Meyer served as a director of Insys Pharma. Mr. Meyer has served as a director of Akorn, Inc., a publicly traded specialty pharmaceutical company, since June 2009. Since November 2005 Mr. Meyer has served as the Chief Financial Officer of JVM Realty Corporation, a private investment firm specializing in the acquisition, re-positioning and management of real estate for investors. Prior to that, Mr. Meyer was employed by Baxter International Incorporated, a global healthcare company, where he served as Corporate Treasurer and International Controller and VP of Global Operations during a 23-year career at this company. Mr. Meyer earned his MBA in finance and accounting from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Economics from the University of Illinois in Champaign-Urbana. He is an Illinois Certified Public Accountant.
- Brian Tambi
-
Brian Tambi ，自2010年11月以来一直是本董事会的成员。他目前是Akorn股份有限公司的董事会成员。在2007年8月-2010年11月期间，他曾在Insys Pharma任董事。自该公司2006年1月成立以来，他曾在一个目前专注于领先单剂药物和传输系统的开发、生产和营销组合的医药公司- BrianT Laboratories有限责任公司任董事长、总裁兼首席执行官。在1995-2007年1月期间，他曾在Morton Grove Pharmaceuticals股份有限公司担任董事长、总裁兼首席执行官。在加入Morton Grove之前，他曾是一个公开上市的被Teva收购的医药公司- Ivax的董事会成员。他还曾在Fujisawa医药公司的子公司- Fujisawa USA股份有限公司担任首席运营官。他还曾在Lyphomed 股份有限公司和Bristol-Myers Squibb担任数个行政管理职位。他是在Syracuse大学获得他的国际金融和经济工商管理学硕士学位，以及企业财务学士学位。
Brian Tambi has served on our Board since November 2010. From August 2007 until the November 2010 Mr. Tambi served as a director of Insys Pharma. Mr. Tambi has served as a member of the Board of Directors of Akorn, Inc., a publicly traded specialty pharmaceutical company, since June 2009. Since forming the company in January 2006 Mr. Tambi has served as the Chairman of the Board, President and Chief Executive Officer of Antrim Pharma formerly BrianT Laboratories LLC, a pharmaceutical company currently focused on developing, manufacturing and marketing combinations of leading single agent drugs and delivery systems. From 1995 to January 2007 Mr. Tambi served as the Chairman, President and Chief Executive Officer of Morton Grove Pharmaceuticals, Inc. Prior to Morton Grove, Mr. Tambi served as President of Ivax North American Pharmaceuticals and as a member of the board of directors of Ivax Corporation (acquired by Teva), a publicly traded pharmaceutical company. Mr. Tambi also served as Chief Operating Officer of Fujisawa USA, Inc., a subsidiary of Fujisawa Pharmaceutical Company, Ltd. Mr. Tambi also held executive positions at Lyphomed, Inc. and Bristol-Myers Squibb. Mr. Tambi earned his MBA in International Finance & Economics and his B.S. in Corporate Finance from Syracuse University. - Brian Tambi ，自2010年11月以来一直是本董事会的成员。他目前是Akorn股份有限公司的董事会成员。在2007年8月-2010年11月期间，他曾在Insys Pharma任董事。自该公司2006年1月成立以来，他曾在一个目前专注于领先单剂药物和传输系统的开发、生产和营销组合的医药公司- BrianT Laboratories有限责任公司任董事长、总裁兼首席执行官。在1995-2007年1月期间，他曾在Morton Grove Pharmaceuticals股份有限公司担任董事长、总裁兼首席执行官。在加入Morton Grove之前，他曾是一个公开上市的被Teva收购的医药公司- Ivax的董事会成员。他还曾在Fujisawa医药公司的子公司- Fujisawa USA股份有限公司担任首席运营官。他还曾在Lyphomed 股份有限公司和Bristol-Myers Squibb担任数个行政管理职位。他是在Syracuse大学获得他的国际金融和经济工商管理学硕士学位，以及企业财务学士学位。
- Brian Tambi has served on our Board since November 2010. From August 2007 until the November 2010 Mr. Tambi served as a director of Insys Pharma. Mr. Tambi has served as a member of the Board of Directors of Akorn, Inc., a publicly traded specialty pharmaceutical company, since June 2009. Since forming the company in January 2006 Mr. Tambi has served as the Chairman of the Board, President and Chief Executive Officer of Antrim Pharma formerly BrianT Laboratories LLC, a pharmaceutical company currently focused on developing, manufacturing and marketing combinations of leading single agent drugs and delivery systems. From 1995 to January 2007 Mr. Tambi served as the Chairman, President and Chief Executive Officer of Morton Grove Pharmaceuticals, Inc. Prior to Morton Grove, Mr. Tambi served as President of Ivax North American Pharmaceuticals and as a member of the board of directors of Ivax Corporation (acquired by Teva), a publicly traded pharmaceutical company. Mr. Tambi also served as Chief Operating Officer of Fujisawa USA, Inc., a subsidiary of Fujisawa Pharmaceutical Company, Ltd. Mr. Tambi also held executive positions at Lyphomed, Inc. and Bristol-Myers Squibb. Mr. Tambi earned his MBA in International Finance & Economics and his B.S. in Corporate Finance from Syracuse University.
- Theodore H. Stanley
-
Theodore H. Stanley，自2013年3月以来一直在本董事会任职。自2009年7月以来，他一直在一个专注于生命科学公司投资的风险投资基金- UpStart Ventures担任总经理，以及自1978年以来，他一直是Utah大学医学院麻醉学系的全职教授。1985年，他联合创立了一家公开上市的专注于经粘膜药物产品（包括其主导的于1983年被Stanley博士联合发明的产品：Actiq）医药公司- Anesta公司。在1985-1997年12月期间，他曾在Anesta担任董事长，以及担任Anesta的医疗主管一直到1994年4月，之后他在1998年1月担任创始董事长一直到2000年10月Anesta出售给了Cephalon。1996年，他联合创立了一个专注于主要在局部痛处给药管理的发展和商业化的私有专业医药公司- ZARS Pharma股份有限公司。Stanley先生在ZARS Pharma担任董事长一直到该公司2011年5月被一个Stanley先生目前任董事的加拿大的（Canadian）私有医药公司-Nuvo Research股份有限公司收购。他还在七个私有生命科学公司董事会任职，在其中4个任董事长。他是在Columbia 大学内科和外科医学院获得他的医学博士学位，以及在Columbia 大学获得他的学士学位的。
Theodore H. Stanley has served on our Board since March 2013. Since July 2009 Dr. Stanley has served as a managing director of UpStart Ventures, a venture capital fund focusing on investments in life sciences companies, and since 1978 Dr. Stanley has been a full time professor in the Department of Anesthesiology at the University of Utah, School of Medicine. In 1985 Dr. Stanley co-founded Anesta Corp., a publicly held pharmaceutical company focusing on the development of transmucosal drug products, including its lead product, Actiq, which was co-invented by Dr. Stanley in 1983. From 1985 to December 1997 Dr. Stanley served as chairman of the board of Anesta and served as Anesta’s Medical Director until April 1994 following which he served as founding chairman from January 1998 until the sale of Anesta to Cephalon in October 2000. In 1996 Dr. Stanley co-founded ZARS Pharma, Inc., a privately held specialty pharmaceutical company that focused on the development and commercialization of topically administered drugs primarily in the area of pain management. Dr. Stanley served as chairman of the board of directors of ZARS Pharma until its acquisition in May 2011 by Nuvo Research Inc., a publicly held Canadian pharmaceutical company, of which Dr. Stanley currently serves as a director. Dr. Stanley also serves on the board of directors of seven privately held life sciences companies, four of which he serves as chairman of the board. Dr. Stanley earned his M.D. degree from Columbia University, College of Physicians and Surgeons Medical Science, as well as an A.B. from Columbia College. - Theodore H. Stanley，自2013年3月以来一直在本董事会任职。自2009年7月以来，他一直在一个专注于生命科学公司投资的风险投资基金- UpStart Ventures担任总经理，以及自1978年以来，他一直是Utah大学医学院麻醉学系的全职教授。1985年，他联合创立了一家公开上市的专注于经粘膜药物产品（包括其主导的于1983年被Stanley博士联合发明的产品：Actiq）医药公司- Anesta公司。在1985-1997年12月期间，他曾在Anesta担任董事长，以及担任Anesta的医疗主管一直到1994年4月，之后他在1998年1月担任创始董事长一直到2000年10月Anesta出售给了Cephalon。1996年，他联合创立了一个专注于主要在局部痛处给药管理的发展和商业化的私有专业医药公司- ZARS Pharma股份有限公司。Stanley先生在ZARS Pharma担任董事长一直到该公司2011年5月被一个Stanley先生目前任董事的加拿大的（Canadian）私有医药公司-Nuvo Research股份有限公司收购。他还在七个私有生命科学公司董事会任职，在其中4个任董事长。他是在Columbia 大学内科和外科医学院获得他的医学博士学位，以及在Columbia 大学获得他的学士学位的。
- Theodore H. Stanley has served on our Board since March 2013. Since July 2009 Dr. Stanley has served as a managing director of UpStart Ventures, a venture capital fund focusing on investments in life sciences companies, and since 1978 Dr. Stanley has been a full time professor in the Department of Anesthesiology at the University of Utah, School of Medicine. In 1985 Dr. Stanley co-founded Anesta Corp., a publicly held pharmaceutical company focusing on the development of transmucosal drug products, including its lead product, Actiq, which was co-invented by Dr. Stanley in 1983. From 1985 to December 1997 Dr. Stanley served as chairman of the board of Anesta and served as Anesta’s Medical Director until April 1994 following which he served as founding chairman from January 1998 until the sale of Anesta to Cephalon in October 2000. In 1996 Dr. Stanley co-founded ZARS Pharma, Inc., a privately held specialty pharmaceutical company that focused on the development and commercialization of topically administered drugs primarily in the area of pain management. Dr. Stanley served as chairman of the board of directors of ZARS Pharma until its acquisition in May 2011 by Nuvo Research Inc., a publicly held Canadian pharmaceutical company, of which Dr. Stanley currently serves as a director. Dr. Stanley also serves on the board of directors of seven privately held life sciences companies, four of which he serves as chairman of the board. Dr. Stanley earned his M.D. degree from Columbia University, College of Physicians and Surgeons Medical Science, as well as an A.B. from Columbia College.
高管简历
中英对照 | 中文 | 英文- Franc Del Fosse
Franc Del Fosse，2014年2月起，担任本公司的法律总顾问。2014年之前，他是律师事务所Snell & Wilmer L.L.P。的合伙人。2005-2014，他是Snell & Wilmer的律师。2001-2005，他是律师事务所Shearman & Sterling的初级合伙人。他在Columbia University School of Law获得法律博士学位，在Arizona State University获得本科学位，是State Bar of California and Arizona的会员。
Franc Del Fosse has served as our General Counsel since February 2014. Prior to joining the Company, Mr. Del Fosse was a partner at the law firm of Snell & Wilmer L.L.P. He was an attorney at Snell & Wilmer from 2005-2014. From 2001-2005 Mr. Del Fosse was an associate at the law firm of Shearman & Sterling. Mr. Del Fosse holds a J.D. degree from Columbia University School of Law and an undergraduate degree from Arizona State University. He is a member of the State Bar of California and Arizona.- Franc Del Fosse，2014年2月起，担任本公司的法律总顾问。2014年之前，他是律师事务所Snell & Wilmer L.L.P。的合伙人。2005-2014，他是Snell & Wilmer的律师。2001-2005，他是律师事务所Shearman & Sterling的初级合伙人。他在Columbia University School of Law获得法律博士学位，在Arizona State University获得本科学位，是State Bar of California and Arizona的会员。
- Franc Del Fosse has served as our General Counsel since February 2014. Prior to joining the Company, Mr. Del Fosse was a partner at the law firm of Snell & Wilmer L.L.P. He was an attorney at Snell & Wilmer from 2005-2014. From 2001-2005 Mr. Del Fosse was an associate at the law firm of Shearman & Sterling. Mr. Del Fosse holds a J.D. degree from Columbia University School of Law and an undergraduate degree from Arizona State University. He is a member of the State Bar of California and Arizona.
- Saeed Motahari
Saeed Motahari自2017年4月17日起担任我们的总裁兼首席执行官兼董事会成员。在加入公司之前，Motahari先生于2014年5月至2017年4月担任Purdue Pharma L.P.的首席商务官。Motahari从2004年到2014年在雅培公司和AbbVie任职，包括担任美国Specialty Brands-New Launchings Vice President。Motahari先生还负责肾脏、肿瘤学、内分泌学、急性护理、病毒学和神经科学治疗领域的专业特许经营。Motahari先生还领导了雅培公司、百时美施贵宝和Hoffmann-La Roche在管理式医疗、商业运营、全球分析和新产品开发方面的各种商业组织。Motahari先生在加拿大蒙特利尔康科迪亚大学（Concordia University）获得生物学学士学位，并持有商学硕士学位。
Saeed Motahari has served as our President and Chief Executive Officer and member of the Board since April 17 2017. Prior to joining the Company, Mr. Motahari served as the Chief Commercial Officer of Purdue Pharma L.P. from May 2014 to April 2017. From 2004 to 2014 Mr. Motahari worked at Abbott Laboratories and AbbVie, including serving as Vice President of US Specialty Brands - New Launches. Mr. Motahari also held P&L responsibility for Specialty Franchises in the Renal, Oncology, Endocrinology, Acute Care, Virology and Neuroscience therapeutic areas. Mr. Motahari has also led various commercial organizations at Abbott Laboratories, Bristol-Myers Squibb and Hoffmann-La Roche in managed care, commercial operations, global analytics and new product development. Mr. Motahari received a BS in Biology and holds a Master’s of Business degree from Concordia University, Montreal, Canada.- Saeed Motahari自2017年4月17日起担任我们的总裁兼首席执行官兼董事会成员。在加入公司之前，Motahari先生于2014年5月至2017年4月担任Purdue Pharma L.P.的首席商务官。Motahari从2004年到2014年在雅培公司和AbbVie任职，包括担任美国Specialty Brands-New Launchings Vice President。Motahari先生还负责肾脏、肿瘤学、内分泌学、急性护理、病毒学和神经科学治疗领域的专业特许经营。Motahari先生还领导了雅培公司、百时美施贵宝和Hoffmann-La Roche在管理式医疗、商业运营、全球分析和新产品开发方面的各种商业组织。Motahari先生在加拿大蒙特利尔康科迪亚大学（Concordia University）获得生物学学士学位，并持有商学硕士学位。
- Saeed Motahari has served as our President and Chief Executive Officer and member of the Board since April 17 2017. Prior to joining the Company, Mr. Motahari served as the Chief Commercial Officer of Purdue Pharma L.P. from May 2014 to April 2017. From 2004 to 2014 Mr. Motahari worked at Abbott Laboratories and AbbVie, including serving as Vice President of US Specialty Brands - New Launches. Mr. Motahari also held P&L responsibility for Specialty Franchises in the Renal, Oncology, Endocrinology, Acute Care, Virology and Neuroscience therapeutic areas. Mr. Motahari has also led various commercial organizations at Abbott Laboratories, Bristol-Myers Squibb and Hoffmann-La Roche in managed care, commercial operations, global analytics and new product development. Mr. Motahari received a BS in Biology and holds a Master’s of Business degree from Concordia University, Montreal, Canada.
- Santosh Vetticaden
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Darryl S. Baker
Darryl S. Baker，自2012年10月以来一直任本公司的财务总监。在2001-2012年期间，他曾在一个移动电气设备的电力管理解决方案和组件的开发商- iGo担任财务总监及公司总管。在2000-2001年期间，他曾在一个安全集成信息技术解决方案的供应商- Integrated Information Systems股份有限公司的公司总管。在1997-1999年期间，他曾在一个综合专业零售商- SkyMall股份有限公司担任企业总管。在1997年前，他曾是Ernst & Young律师事务所的一个审计经理。他拥有着会计、小型上市公司SEC遵行、合并和收购交易以及小企业融资的丰富经验，以及经常是专业教育中心的各种热点问题的专家和讲师，这些问题包括SEC遵行、股票薪酬、收入确认、公允价值和租赁会计。他是在Brigham Young大学Marriott管理学院获得他的会计学士学位，以及是California和Arizona州的注册会计师，还是一位注册的全球管理会计师。
Darryl S. Baker has served as our Chief Financial Officer since October 2012. From 2001 to 2012 Mr. Baker served as Chief Financial Officer and Corporate Controller for iGo, a developer of power management solutions and accessories for mobile electronic devices. From 2000 to 2001 Mr. Baker served as the Corporate Controller for Integrated Information Systems, Inc., a provider of secure integrated information technology solutions. From 1997 to 1999 Mr. Baker served as the Corporate Controller for SkyMall, Inc., a specialty retailer. Prior to 1997 Mr. Baker was an audit manager for Ernst & Young. Mr. Baker earned his B.S. in Accountancy from the Marriott School of Management at Brigham Young University and is a Certified Public Accountant in the states of California and Arizona and is also a Chartered Global Management Accountant.- Darryl S. Baker，自2012年10月以来一直任本公司的财务总监。在2001-2012年期间，他曾在一个移动电气设备的电力管理解决方案和组件的开发商- iGo担任财务总监及公司总管。在2000-2001年期间，他曾在一个安全集成信息技术解决方案的供应商- Integrated Information Systems股份有限公司的公司总管。在1997-1999年期间，他曾在一个综合专业零售商- SkyMall股份有限公司担任企业总管。在1997年前，他曾是Ernst & Young律师事务所的一个审计经理。他拥有着会计、小型上市公司SEC遵行、合并和收购交易以及小企业融资的丰富经验，以及经常是专业教育中心的各种热点问题的专家和讲师，这些问题包括SEC遵行、股票薪酬、收入确认、公允价值和租赁会计。他是在Brigham Young大学Marriott管理学院获得他的会计学士学位，以及是California和Arizona州的注册会计师，还是一位注册的全球管理会计师。
- Darryl S. Baker has served as our Chief Financial Officer since October 2012. From 2001 to 2012 Mr. Baker served as Chief Financial Officer and Corporate Controller for iGo, a developer of power management solutions and accessories for mobile electronic devices. From 2000 to 2001 Mr. Baker served as the Corporate Controller for Integrated Information Systems, Inc., a provider of secure integrated information technology solutions. From 1997 to 1999 Mr. Baker served as the Corporate Controller for SkyMall, Inc., a specialty retailer. Prior to 1997 Mr. Baker was an audit manager for Ernst & Young. Mr. Baker earned his B.S. in Accountancy from the Marriott School of Management at Brigham Young University and is a Certified Public Accountant in the states of California and Arizona and is also a Chartered Global Management Accountant.